Innate Pharma Files 6-K, Announces Press Release
Ticker: IPHYF · Form: 6-K · Filed: Jan 21, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Jan 21, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Innate Pharma dropped a 6-K on Jan 21, 2025 - check the press release for deets.
AI Summary
Innate Pharma SA filed a Form 6-K on January 21, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or operational details beyond the announcement of the press release.
Why It Matters
This filing indicates Innate Pharma is providing an update to the market, likely containing important company news or developments.
Risk Assessment
Risk Level: low — This is a routine filing that primarily announces the release of a press release, with no immediate financial or operational disclosures.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- January 21, 2025 (date) — Date of report and press release
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report a press release issued by Innate Pharma SA on January 21, 2025.
What is the filing date of this Form 6-K?
The Form 6-K was filed on January 21, 2025.
Does Innate Pharma SA file annual reports under Form 20-F or 40-F?
Innate Pharma SA indicates it files annual reports under Form 20-F.
What is the principal executive office address for Innate Pharma SA?
The principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
What exhibit is included with this 6-K filing?
Exhibit 1.1 is a Press Release dated January 21, 2025.
Filing Stats: 164 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2025-01-21 06:00:54
Filing Documents
- a6k-iphx250121.htm (6-K) — 8KB
- exhibit991-250121.htm (EX-99.1) — 18KB
- 0001598599-25-000005.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date January 21, 2025 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chairman of the Executive Board and Chief Executive officer